Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Syndax Pharmaceuticals excels in Q4, poised for growth in 2023

Syndax Pharmaceuticals demonstrated strong financial and developmental performance in Q4 2022, with promising advancements in Revumenib and axatilimab.
While facing challenges in FDA considerations and safety data optimization, Syndax is well-positioned to capitalize on opportunities in expanding market reach and strategic partnerships.
The company's clear financial guidance, enrollment progress, and strategic initiatives underscore a positive outlook for future growth and commercial success.

Syndax Pharmaceuticals reports strong financials and advances key drug candidates

Syndax Pharmaceuticals shows strong financial position with a focus on pivotal drug candidates.
Analyst interest in drug efficacy and trial progress highlights market engagement.
Challenges include financial losses, specific patient response data, and trial design considerations.
Opportunities lie in growth potential, market expansion, and strategic partnerships.

Syndax Pharmaceuticals reports Q2 progress with focus on innovative treatments

Syndax Pharmaceuticals' Q2 performance reflects financial stability with a focus on promising trial outcomes.
Strengths lie in innovative drug development, market reach strategies, and a differentiated treatment approach.
Challenges include regulatory hurdles, commercialization decisions, and managing financial resources effectively.
Opportunities arise from upcoming data releases, market penetration plans, and showcasing treatment differentiators.

Syndax Pharmaceuticals reports positive trial data and financial stability

Syndax Pharmaceuticals showcases strong performance in pivotal trials, supported by a solid financial position and a focus on expanding into new indications.
Challenges include enrollment diversity and breakthrough therapy designation, but opportunities lie in market expansion and personalized treatment approaches.
Overall, Syndax is well-positioned to advance its pipeline and deliver innovative therapies for leukemia patients, with a focus on quality data and strategic growth.

Syndax Pharmaceuticals advances key drugs towards potential approvals and commercialization

Syndax Pharmaceuticals made notable progress in 2023, positioning itself for potential drug approvals and commercialization in 2024.
While facing challenges in market competition and regulatory processes, the company's strategic collaborations and pipeline advancements signal a proactive growth trajectory.
With a strong financial position, ongoing clinical trials, and a focus on refining dosing strategies, Syndax is poised to capitalize on market opportunities and drive innovation in oncology.

Syndax Pharmaceuticals reports strong Q1 performance and readies for transformative year ahead

Syndax Pharmaceuticals showcased strong performance, financial stability, and commercial readiness in their Q1 2024 Earnings Call, highlighting a promising outlook for the company's future.
While facing challenges in patient response rates and market adoption, Syndax's robust pipeline, strategic financial planning, and commercial expertise position it well for growth and success.
With opportunities for retreatment strategies, regulatory expedited pathways, and new market engagements, Syndax is poised for a transformative year ahead, leveraging its strengths to drive innovation and market expansion.

Syndax Pharmaceuticals excels in Q3 with FDA approvals and strategic partnerships

Syndax Pharmaceuticals delivered a strong performance in Q3 2024, marked by FDA approvals and strategic partnerships. Their financial position is robust, setting the stage for successful commercialization and future pipeline advancements. While challenges exist in a competitive landscape, the company's innovative pipeline and market opportunities position them for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options

WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from the Company's Phase 1 trial of...

Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast...

Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts

WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive...

Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript

WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352

Syndax Pharmaceuticals stock tumbled to a month-low Friday after the biotech's breast cancer treatment failed in a Phase 3 test. Syndax says it won't be asking for FDA approval.

Syndax Pharmaceuticals Crashes On Late-Stage Failure In Breast Cancer

WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that...

ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q1 2020 Results - Earnings Call Transcript

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Initial data from an early-stage leukemia trial is promising.

Why Syndax Is Skyrocketing 55% Today

Shares of Syndax Pharmaceuticals soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment in leukemia patients.
The post Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High appeared first on Investor's Business Daily.

Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.

Will Syndax Pharmaceuticals Continue to Surge Higher?

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2019 Results - Earnings Call Transcript

Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss

As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2019 Results - Earnings Call Transcript

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates

Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know

Apellis Pharma

Medicines

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

Implied Volatility Surging for Syndax (SNDX) Stock Options

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2019 Results - Earnings Call Transcript

News for Syndax Pharmaceuticals Stock (SNDX)